Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal a mixed outlook. Positive elements include stable fiscal year '26 guidance, potential growth from AI capabilities, and interest in acquisitions. However, challenges such as a significant drop in Pro-ficiency software revenue, cautious large pharma, and current renewal rates in the low to mid-80% range offset these positives. The lack of significant changes in guidance assumptions and the absence of major cancellations provide stability, but the overall sentiment remains neutral due to the balancing of positive and negative factors.
Key Financial Performance
Total Revenue (Q4) $17.5 million, a decrease of 6% year-over-year. The decline was attributed to market conditions and client consolidations.
Total Revenue (Fiscal Year) $79.2 million, an increase of 13% year-over-year. Growth was driven by increases in both software and services revenue.
Software Revenue (Q4) Decreased 9%, representing 52% of total revenue. Decline due to market conditions and client consolidations.
Software Revenue (Fiscal Year) Increased 12%, representing 58% of total revenue. Growth driven by product performance and client demand.
Services Revenue (Q4) Decreased 3%, representing 48% of total revenue. Decline due to expected market conditions.
Services Revenue (Fiscal Year) Increased 15%, representing 42% of total revenue. Growth primarily due to the addition of the Med Comm business.
Gross Margin (Fiscal Year) 58%, down from 62% last year. Software gross margin was 79% (down from 84%), and services gross margin remained at 30%. Decline in software gross margin was due to increased amortization expenses.
Net Loss (Fiscal Year) $64.7 million, compared to net income of $10 million last year. Loss includes a $77.2 million noncash impairment charge.
Adjusted Diluted EPS (Fiscal Year) $1.03, an increase from $0.95 last year. Growth reflects operational improvements.
Adjusted EBITDA (Fiscal Year) $22 million, an increase from $20.3 million last year. Growth driven by revenue increases and operational efficiency.
Cash and Short-Term Investments (End of Fiscal Year) $32.4 million, with no debt and strong free cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GastroPlus 10.2: Released earlier this year as part of the groundwork for future biosimulation capabilities.
Integrated Product Ecosystem: Combines validated science, cloud-scale performance, and AI-driven services into a unified ecosystem for discovery, clinical development, and commercialization.
Biosimulation Demand: Momentum behind biosimulation is accelerating as biopharma and regulatory partners scale internal model development capabilities and invest in AI and digital infrastructure.
Client Budget Stabilization: Signs of stabilization in client budgets as large pharma gains visibility into pricing frameworks and biotech funding improves modestly.
Unified Operating Model: Transitioned to a unified operating model aligning product, technology, R&D, consulting, and business development into a client-focused structure.
Revenue and Client Metrics: Fiscal year revenue grew 13% to $79.2 million, with an average revenue per client of $143,000 and an 88% renewal rate.
Strategic Reset: 2025 marked a strategic reset with a focus on integrating scientific engines, cloud infrastructure, and AI capabilities into a biosimulation ecosystem.
Future Roadmap: Plans to share more details about the integrated product strategy and roadmap at the virtual Investor Day in January 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Client Budget Pressures: Client budgets were pressured by broader pharmaceutical headwinds, including the threat of tariffs and most favored nation pricing implementation, causing disruptions starting midyear.
Market Uncertainty: Uncertainty in the overall environment is expected to persist in the near term, despite early signs of stabilization in large pharma pricing frameworks and modest improvement in biotech funding.
Decline in Software Revenue: Software revenue decreased 9% in the fourth quarter, with specific declines in products like ADMET Predictor and GastroPlus, attributed to market conditions and client consolidations.
Services Revenue Challenges: Services revenue for certain solutions, such as PBPK and QSP services, declined significantly for the quarter and fiscal year, reflecting challenges in maintaining growth in these areas.
Gross Margin Decline: Total gross margin decreased to 58% from 62% in the prior year, primarily due to increased amortization expenses related to acquisitions and software development costs.
Noncash Impairment Charge: A $77.2 million noncash impairment charge significantly impacted total operating expenses, increasing them to 148% of revenue compared to 53% last year.
First Quarter Revenue Decline Expectation: First quarter revenue for fiscal 2026 is anticipated to be 3% to 5% lower than the same period last year, reflecting ongoing market challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Market Conditions and Client Spending: The company expects fiscal year 2026 market conditions to resemble those at the close of fiscal year 2025, with a stable operating environment. However, should market conditions improve and clients increase spending, the company is prepared to respond.
Revenue Guidance for Fiscal Year 2026: Total revenue is projected to be between $79 million to $82 million, representing year-over-year growth of 0% to 4%.
Revenue Mix: The software mix is expected to range between 57% to 62% of total revenue.
Adjusted EBITDA Margin: The adjusted EBITDA margin is anticipated to be between 26% to 30%.
Adjusted Diluted Earnings Per Share: Adjusted diluted EPS is projected to be between $1.03 to $1.10.
First Quarter Revenue Guidance: First quarter revenue is expected to be approximately 3% to 5% lower than the same period last year.
Tax Rate for Fiscal Year 2026: The effective tax rate is expected to be in the range of 12% to 14%.
Product and Strategy Development: The company plans to focus on integrating its scientific engines, cloud infrastructure, and AI capabilities into a unified biosimulation ecosystem. This includes updates across products like GastroPlus, MonolixSuite, ADMET Predictor, and others in fiscal 2026.
Client and Market Trends: Clients are increasingly adopting biosimulation as a core component of R&D, with a focus on faster cycle times, AI-assisted workflows, and regulatory-grade modeling. The company is positioned to address these needs with its integrated product ecosystem.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the demand environment, including recent trends and factors like RFP volumes, pipeline development, and SLPs win rate?
A:Shawn O'Connor noted an uptick in biotech funding, which supports about 25% of their client base. Large pharma showed mixed results but mostly positive trends. Budgeting activity for the next year appears to have momentum, though caution remains due to potential market surprises. Overall, the company enters fiscal year '26 on good footing.
Q:What feedback have you received on the GastroPlus release infused with AI capabilities, and how is it impacting client discussions?
A:Shawn O'Connor stated that initial client response to GastroPlus has been positive. Clients are digesting the new AI capabilities, which align with their evolving IT infrastructures. Adoption will depend on client timetables, but there is excitement about the platform's advanced functionality.
Q:What factors might still cause large pharma to be cautious despite improvements in pricing, tariffs, and funding?
A:Shawn O'Connor mentioned that large pharma's caution is influenced by individual circumstances like drug program outcomes and patent expirations. Budgeting for 2025 is stable, and momentum for 2026 budgets is positive. However, market surprises could still impact confidence and spending.
Q:Do you have the right headcount to support a higher revenue base if bookings and backlog increase?
A:Shawn O'Connor explained that the software side is leverageable without immediate headcount needs. On the services side, current capacity is sufficient for fiscal year '26 guidance. If demand accelerates, the company is confident in its ability to grow capacity quickly.
Q:Has anything changed in the assumptions underlying your guidance since it was provided in October?
A:Shawn O'Connor stated that no significant changes have occurred. Fiscal year '26 guidance reflects stability in revenue flow, with normal seasonality patterns and challenging year-over-year comparisons in the first quarter. The guidance assumes 0% to 4% growth for the year.
Q:Does your guidance assume any recovery in the biotech end market, and how do you view cancellation risks?
A:Shawn O'Connor noted that the guidance does not assume a significant biotech recovery, though continued funding could provide upside. Cancellation risks are factored into forecasts, with no known major cancellations for fiscal year '26. The company remains cautious but prepared to manage cancellations.
Q:What factors are weighing on software renewal rates, and when might they return to 90%?
A:Shawn O'Connor attributed lower renewal rates to client consolidations and scrutiny of software configurations. Renewal rates are expected to improve as consolidation impacts lessen and price increases take effect. The company anticipates a return to 90% renewal rates over time.
Q:What is baked into your EBIT margin guidance for fiscal year '26, and how will margins evolve over the year?
A:Shawn O'Connor explained that cost reductions and modest top-line growth contribute to the 26% to 30% adjusted EBITDA margin guidance. Margins will improve with higher revenue growth, but significant improvement requires top-line growth above 10%.
Q:Why was Pro-ficiency software revenue down significantly in the fourth quarter, and what is the revenue mix between software and services?
A:Shawn O'Connor noted a slowdown in clinical trial starts impacting Pro-ficiency software revenue, which was down 63% year-over-year. Pro-ficiency revenue is approximately 40% software and 60% services.
Q:How much visibility do you have into first-quarter revenue, and what percentage of revenue is under contract?
A:Shawn O'Connor stated that first-quarter revenue guidance reflects good visibility, with tracking aligned to expectations. Revenue growth percentages will improve in the back half of fiscal year '26 due to easier year-over-year comparisons.
Q:Does your fiscal year '26 guidance assume recent renewal trends in the low to mid-80% range?
A:Shawn O'Connor confirmed that guidance assumes renewal trends in the low to mid-80% range, with higher price increases factored in to support revenue growth.
Q:What is your level of interest in acquisitions, and what markets are you targeting?
A:Shawn O'Connor stated that the company remains interested in acquisitions in biosimulation and clinical operations. Fiscal year '26 may provide opportunities for acquisitions following the integration of the Pro-ficiency acquisition in fiscal year '25.
Q:What pricing flexibility do you have, and how does it factor into fiscal year '26 guidance?
A:Shawn O'Connor explained that pricing flexibility is supported by new AI and cloud capabilities. Price increases are baked into the guidance but discounted for yield and timing. On the services side, price competition remains high, limiting significant price increases.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific percentage of Pro-ficiency revenue that comes from software versus services, providing only an approximate mix. Additionally, while they discussed pricing flexibility and renewal trends, the responses lacked detailed numerical data or specific timelines for improvement.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADMET Predictor
AI service
Development product
Discovery product
FY
RD team
biosimulation
capability
charge income
cloud
condition client
curation
discovery development
ecosystem
engine
expense
ficiency
grade
income decrease
infrastructure AI
market condition
model development
model product
modeling
rate
release GastroPlus
rigor
science scale
shift
software margin
solution
tax
workflow
SLP Transcript
Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
Unknown4-9
The earnings call reveals mixed signals: strong software and services margins, new customer acquisitions, and a healthy cash position are positive. However, the cautious revenue guidance, increased tax expense, and lack of AI monetization in FY '26 are concerns. The Q&A highlighted uncertainties in guidance adjustments and macroeconomic factors, tempering optimism. These factors suggest a neutral stock price movement over the next two weeks.
Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript
Unknown1-8
The earnings call summary presents a mixed outlook. While there is positive news about software performance peaking and MedCom exceeding expectations, challenges exist with clinical operations software revenue and tough comparisons. The Q&A section reveals cautious optimism with no change in guidance and AI integration showing promise. However, management's avoidance of specific details and the lack of new verticals or products in the near term suggest limited immediate catalysts. Consequently, the stock is likely to remain neutral over the next two weeks.
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Unknown12-1
The earnings call summary and Q&A session reveal a mixed outlook. Positive elements include stable fiscal year '26 guidance, potential growth from AI capabilities, and interest in acquisitions. However, challenges such as a significant drop in Pro-ficiency software revenue, cautious large pharma, and current renewal rates in the low to mid-80% range offset these positives. The lack of significant changes in guidance assumptions and the absence of major cancellations provide stability, but the overall sentiment remains neutral due to the balancing of positive and negative factors.
Simulations Plus, Inc. (SLP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-11
SLP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
